title: Renal effects of S10036 in man.
abstract: The renal hemodynamic and tubular effects of S10036 (fotemustine) were evaluated in seven patients with advanced malignancy. Initial evaluation carried out prior to treatment and repeated 1 day after the first fotemustine infusion and 7 days after the second included clinical, haematological parameters, liver-function tests, and determination of the glomerular filtration rate, renal blood flow and enzymuria. The glomerular filtration rate was 108 +/- 3.7 ml/min before treatment and remained stable after the first (117 +/- 5 ml/min) and second (124 +/- 6 ml/min) fotemustine infusions. Renal blood flow and urinary beta 2-microglobulin and N'-acetylglucosaminidase excretion were also not modified by fotemustine administration. We conclude that fotemustine does not acutely alter renal haemodynamics, nor does it have direct tubular toxicity.
authors.affiliation: Department of Nephrology, Hopital Pitié-Salpêtrière, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Deray
authors.forename: D
authors.initials: D
authors.lastname: Khayat
authors.forename: C
authors.initials: C
authors.lastname: Jacquiaud
authors.forename: J P
authors.initials: JP
authors.lastname: Bizzari
authors.forename: R
authors.initials: R
authors.lastname: Bourbouze
authors.forename: L
authors.initials: L
authors.lastname: Musset
authors.forename: M C
authors.initials: MC
authors.lastname: Jaudon
authors.forename: B
authors.initials: B
authors.lastname: Baumelou
authors.forename: C
authors.initials: C
authors.lastname: Jacquillat
authors.forename: C
authors.initials: C
authors.lastname: Jacobs
mesh_terms: D000118:Acetylglucosaminidase / Q000652:urine; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006400:Hematocrit; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007684:Kidney Tubules / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012079:Renal Circulation / Q000187:drug effects; D001613:beta 2-Microglobulin / Q000652:urine
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D001613:beta 2-Microglobulin; D000118:Acetylglucosaminidase; C054368:fotemustine